Search results
Results from the WOW.Com Content Network
This distinction must be made by both the treating physicians and the cancer patients themselves. Many oncologists in their daily clinical practice follow their patients' malignant disease by means of repeated imaging studies and make decisions about continuing therapy on the basis of both objective and symptomatic criteria.
In addition, discrimination of synchronous lesions that have a different nature is also important knowing that up to 25–50% of liver lesions less than 2 cm detected in cancer patients may be benign . US sensitivity for metastases detection varies depending on the examiner's experience and the equipment used and ranges between 40 and 80% .
The success of lithotripsy depends on the size and location of the stone, and the patient's age. [10] Oncology. Ultrasound can ablate tumors or other tissue non-invasively. [4] This is accomplished using a technique known as high intensity focused ultrasound (HIFU), also called focused ultrasound surgery. This procedure uses generally lower ...
Ultrasound is the preferred imaging modality for thyroid tumors and lesions, and its use is important in the evaluation, preoperative planning, and postoperative surveillance of patients with thyroid cancer. Many other benign and malignant conditions in the head and neck can be differentiated, evaluated, and managed with the help of diagnostic ...
In 2003, Yao et al. reported experience at the University of California San Francisco five-year post-transplantation survival of 75% in patients with tumors as large as 6.5 cm, or up to three lesions each less than 4.5 cm with cumulative tumor burden ≤8 cm. [4] Additional studies using these so-called "UCSF criteria" have shown favorable post ...
Transrectal ultrasonography, or TRUS in short, is a method of creating an image of organs in the pelvis, most commonly used to perform an ultrasound-guided needle biopsy evaluation of the prostate gland in men with elevated prostate-specific antigen or prostatic nodules on digital rectal exam.
Studies on localized prostate cancer showed that, after treatment, progression-free survival rates were high for low- and intermediate- risk patients with recurrent prostate cancer. [2] The InsighTec ExAblate 2000 was the first MRgFUS system to obtain FDA market approval, [3] US patent 5,247,935.
Survival with a transjugular intrahepatic portosystemic shunt (TIPS) versus a DSRS is thought to be approximately similar, [4] [5] but still an area of intensive research. [6] [7] Both TIPS and DSRS lead to decreased rates of variceal bleeding at the expense of hepatic encephalopathy; however, TIPS appears to have more shunt dysfunction and ...